Timothy Card1, Ryan Ungaro2, Fatima Bhayat3, Aimee Blake3, Gary Hantsbarger3, Simon Travis4. 1. Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK. 2. The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Takeda Pharmaceuticals International Co., Cambridge, MA, USA. 4. Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Abstract
BACKGROUND: Vedolizumab is a gut-selective antibody to α4 β7 integrin approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of malignancy. AIM: To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI long-term safety (LTS) study and post-marketing (PM) setting. METHODS: Malignancy data from the LTS study (May 2009 to May 2018), and data from the vedolizumab Global Safety Database (20 May 2014 to 19 May 2018), were identified using Medical Dictionary for Regulatory Activities coding. The number of patients experiencing malignancies in the LTS study (excluding malignancies within 1 year following vedolizumab initiation) was indirectly standardised against the number expected, using age- and sex-specific rates in patients with IBD from Optum's Clinformatics™ Data Mart (CDM) database. RESULTS: Among 1785 patients with ≥1 year of follow-up post-vedolizumab initiation in the LTS study (total 5670 patient-years), observed numbers of malignancies were similar to those expected compared with CDM data (31 vs 29; ratio of observed to expected events = 1.08; P = 0.71; 95% confidence intervals [CI] 0.73, 1.53). The most common malignancies were renal and bladder (6). PM, 293 patients reported 299 malignancies (including malignancies within 1 year following vedolizumab initiation), in approximately 208 050 patient-years of vedolizumab exposure. Lower gastrointestinal malignancies were most common (59). CONCLUSIONS: The number of malignancies in the LTS study was similar to that expected from an IBD population with no statistically significant differences, although few confounders could be corrected for. Limitations of PM safety reporting require consideration; however, the number of malignancies with vedolizumab appeared low.
BACKGROUND:Vedolizumab is a gut-selective antibody to α4 β7 integrin approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of malignancy. AIM: To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI long-term safety (LTS) study and post-marketing (PM) setting. METHODS:Malignancy data from the LTS study (May 2009 to May 2018), and data from the vedolizumab Global Safety Database (20 May 2014 to 19 May 2018), were identified using Medical Dictionary for Regulatory Activities coding. The number of patients experiencing malignancies in the LTS study (excluding malignancies within 1 year following vedolizumab initiation) was indirectly standardised against the number expected, using age- and sex-specific rates in patients with IBD from Optum's Clinformatics™ Data Mart (CDM) database. RESULTS: Among 1785 patients with ≥1 year of follow-up post-vedolizumab initiation in the LTS study (total 5670 patient-years), observed numbers of malignancies were similar to those expected compared with CDM data (31 vs 29; ratio of observed to expected events = 1.08; P = 0.71; 95% confidence intervals [CI] 0.73, 1.53). The most common malignancies were renal and bladder (6). PM, 293 patients reported 299 malignancies (including malignancies within 1 year following vedolizumab initiation), in approximately 208 050 patient-years of vedolizumab exposure. Lower gastrointestinal malignancies were most common (59). CONCLUSIONS: The number of malignancies in the LTS study was similar to that expected from an IBD population with no statistically significant differences, although few confounders could be corrected for. Limitations of PM safety reporting require consideration; however, the number of malignancies with vedolizumab appeared low.
Authors: Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer Journal: Gastroenterology Date: 2014-05-21 Impact factor: 22.682
Authors: Tim R A van den Heuvel; Dion S J Wintjens; Steven F G Jeuring; Maartje H H Wassink; Marielle J L Romberg-Camps; Liekele E Oostenbrug; Silvia Sanduleanu; Wim H Hameeteman; Maurice P Zeegers; Ad A Masclee; Daisy M Jonkers; Marie J Pierik Journal: Int J Cancer Date: 2016-05-31 Impact factor: 7.396
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Sverre Söderlund; Lena Brandt; Annika Lapidus; Per Karlén; Olle Broström; Robert Löfberg; Anders Ekbom; Johan Askling Journal: Gastroenterology Date: 2009-05 Impact factor: 22.682
Authors: David S Kotlyar; James D Lewis; Laurent Beaugerie; Ann Tierney; Colleen M Brensinger; Javier P Gisbert; Edward V Loftus; Laurent Peyrin-Biroulet; Wojciech C Blonski; Manuel Van Domselaar; Maria Chaparro; Sandipani Sandilya; Meenakshi Bewtra; Florian Beigel; Livia Biancone; Gary R Lichtenstein Journal: Clin Gastroenterol Hepatol Date: 2014-05-28 Impact factor: 11.382
Authors: Severine Vermeire; Edward V Loftus; Jean-Frédéric Colombel; Brian G Feagan; William J Sandborn; Bruce E Sands; Silvio Danese; Geert R D'Haens; Arthur Kaser; Remo Panaccione; David T Rubin; Ira Shafran; Megan McAuliffe; Arpeat Kaviya; Serap Sankoh; Reema Mody; Brihad Abhyankar; Michael Smyth Journal: J Crohns Colitis Date: 2017-04-01 Impact factor: 9.071